Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Raw Materials (2019 - 2025)

Pulmonx (LUNG) has disclosed Raw Materials for 7 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Raw Materials rose 26.29% to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.3 million, a 26.29% increase, with the full-year FY2024 number at $3.4 million, up 16.48% from a year prior.
  • Raw Materials was $4.3 million for Q3 2025 at Pulmonx, up from $3.9 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $4.3 million in Q3 2025 to a low of $2.9 million in Q3 2023.
  • A 5-year average of $3.5 million and a median of $3.4 million in 2024 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: fell 23.46% in 2023, then soared 30.01% in 2025.
  • Pulmonx's Raw Materials stood at $3.7 million in 2021, then grew by 2.19% to $3.8 million in 2022, then dropped by 23.46% to $2.9 million in 2023, then grew by 16.48% to $3.4 million in 2024, then grew by 24.96% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Raw Materials are $4.3 million (Q3 2025), $3.9 million (Q2 2025), and $3.4 million (Q1 2025).